Views & Analysis
Category : Views & Analysis / Clinical
Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.
What does it take to establish new treatments for rare diseases?
For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.
The demand for high-calibre, sharply-focussed clinical knowledge and data is increasing as HCPs streamline and recalibrate their engagements with the pharmaceutical sector. But, al
Thanks to constant advances in technology and science, artificial intelligence (AI) is rapidly becoming an integral part of modern healthcare.
2023 is set to be a landmark year for lipid-based delivery technology development and the 2nd Next-Generation Lipid-Based Nanoparticle Delivery Summit re
Not only has the pandemic fuelled interest in new modalities research, but it has also triggered a renaissance of formulation approaches amongst biopharma to bring new wave of drug substances and t
Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox